LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report) today and set a price target of $33.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Rami Katkhuda’s rating is based on Mineralys Therapeutics, Inc.’s promising financial position and upcoming pivotal data in their hypertension studies. The company reported robust FY 2024 earnings with $198.2 million in cash and investments, projected to sustain operations through Q1 2026. This financial stability supports the potential transformative impact expected in H1 2025 from the results of two pivotal hypertension studies and a proof-of-concept CKD study.
Furthermore, the ongoing lorundrostat trials, specifically Advance-HTN, are on schedule with anticipated results by March. This study is notable for its rigorous design, employing a standardized regimen and advanced monitoring techniques. With significant enrollment diversity and expert opinions suggesting potential successful outcomes, these studies could position Mineralys for substantial growth if they meet or exceed expectations in terms of blood pressure reduction and safety metrics.
Katkhuda covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Disc Medicine, and VYNE Therapeutics. According to TipRanks, Katkhuda has an average return of 26.6% and a 45.45% success rate on recommended stocks.